MARKET

MYOV

MYOV

MYOVANT SCIENCES
NYSE

Real-time Quotes | Nasdaq Last Sale

20.03
-0.12
-0.60%
After Hours: 20.00 -0.03 -0.15% 16:12 07/02 EDT
OPEN
20.32
PREV CLOSE
20.15
HIGH
20.44
LOW
19.83
VOLUME
569.35K
TURNOVER
--
52 WEEK HIGH
22.07
52 WEEK LOW
4.140
MARKET CAP
1.80B
P/E (TTM)
-5.9362
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MYOV stock price target is 31.33 with a high estimate of 55.00 and a low estimate of 20.00.

EPS

MYOV News

More
Goldman Sachs: Theres an Opportunity Brewing in These 3 Stocks
TipRanks · 2d ago
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer
CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE NEWSWIRE) -- BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV) today announced the launch of Forward Momentum, a cross-sector coa
GlobeNewswire · 3d ago
Karuna Program Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/26 05:42
Company News for Jun 24, 2020
Zacks · 06/24 14:29
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Zacks · 06/24 14:12
Myovant Sciences's relugolix combo successful in second late-stage endometriosis study
Seeking Alpha - Article · 06/23 18:33
Myovant's stock gains on promising endometriosis drug trial
MarketWatch · 06/23 14:02
INO, PEI among premarket gainers
Seeking Alpha - Article · 06/23 12:27

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About MYOV

Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.
More

Webull offers kinds of Myovant Sciences Ltd stock information, including NYSE:MYOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOV stock methods without spending real money on the virtual paper trading platform.